UMR Inserm U930, Université François-Rabelais de Tours, Tours, France.
CHRU de Tours; INSERM CIC 1415, 37000, Tours, France.
Sci Rep. 2017 Jul 24;7(1):6211. doi: 10.1038/s41598-017-06089-z.
Thrombosis is a major cause of several diseases, i.e. myocardial infarction, cerebral stroke and pulmonary embolism. Thrombolytic therapies are required to induce fast and efficient recanalization of occluded vessels. To evaluate the in vitro efficacy of these thrombolytic strategies, measuring clot dissolution is essential. This study aimed to evaluate and validate high resolution ultrasound as a tool to assess the exact volume of clots in 3D and in real time during in vitro thrombolytic drug testing. This new method was validated by measuring the effects of concentration range of recombinant tissue type plasminogen activator on a blood clot during complete occlusion or 70% stenosis of a vessel. This study shows that high resolution ultrasound imaging allows for a real-time assessment of the 3D volume of a blood clot with negligible inter- and intra-operator variabilities. The conclusions drawn from this study demonstrate the promising potential of high resolution ultrasound imaging for the in vitro assessment of new thrombolytic drugs.
血栓形成是多种疾病的主要原因,例如心肌梗死、脑卒中和肺栓塞。需要溶栓疗法来快速有效地使闭塞的血管再通。为了评估这些溶栓策略的体外疗效,测量血栓溶解至关重要。本研究旨在评估和验证高分辨率超声作为一种工具,用于在体外溶栓药物测试过程中实时评估 3D 中血栓的确切体积。通过测量重组组织型纤溶酶原激活剂的浓度范围对完全闭塞或血管 70%狭窄时的血栓的影响来验证这种新方法。本研究表明,高分辨率超声成像允许实时评估血栓的 3D 体积,且操作者间和操作者内的可变性可忽略不计。本研究得出的结论表明,高分辨率超声成像对于新溶栓药物的体外评估具有很大的潜力。